| |
BPDCN: Blastic plasmacytoid dendritic cell neoplasm
Having trouble viewing this e-mail? View on web
|
|
|
|
| |
| |
CD123 SHOULD BE ADDED TO INITIAL
HEMATOLOGIC DIAGNOSTIC PANELS.1
|
Learn more
|
|
|
| |
| |
Dear Healthcare Provider,
|
|
| |
| |
CD123 has been established as a critical identifier in the diagnosis of BPDCN, along with other markers commonly included on hematologic diagnostic panels.* Delays in diagnosis often lead to ineffective disease management and poor outcomes for patients.1,2
|
|
| |
| |
Add CD123 to initial hematologic panels
|
|
| |
| |
|
CD123 is rapidly emerging as a therapeutic target in hematologic cancer.1
CD123, as part of the signature marker triad in combination with CD4 and CD56, is a key marker in identifying BPDCN—a particularly aggressive hematologic cancer that often presents with skin lesions.1,3
Adding CD123 to initial hematologic diagnostic panels is critical for an accurate diagnosis of BPDCN.1
|
|
|
| |
| |
Visit BPDCNinfo.com for more information.
|
|
| |
| |
*BPDCN diagnosis can include other markers, such as CD4, CD56, TCL1, and CD303 (BDCA2).4
References: 1. Pagano L, Valentini CG, Grammatico S, Pulsoni A. Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches. Br J Haematol. 2016;174(2):188-202. 2. Frankel AE, Woo JH, Ahn C, et al. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014;124(3):385-392. 3. Riaz W, Zhang L, Horna P, Sokol L. Blastic plasmacytoid dendritic cell neoplasm: update on molecular biology, diagnosis, and therapy. Cancer Control. 2014;21(4):279-289. 4. Reichard KK. Blastic plasmacytoid dendritic cell neoplasm: how do you distinguish it from acute myeloid leukemia? Surg Pathol Clin. 2013;6(4):743-765. |
|
| |
| |
|
|
| |
| |
|
| |
| |
If you prefer not to receive further messages from this sender, please click here and confirm your request.
Contact Us
Site Map
Legal Statement
Privacy Notice
|
|
